cetuximab
FDA Approves Pfizer's Braftovi With Eli Lilly's Erbitux, Chemo in Colorectal Cancer
The agency granted accelerated approval to the regimen as a frontline option for advanced, BRAF V600E-mtuated tumors based on the BREAKWATER trial.
FDA Approves BMS's Krazati With Cetuximab for KRAS G12C-Mutated Colorectal Cancer
BMS had submitted an application with the FDA earlier this year for approval of the drug with Erbitux for this patient population.
Boundless Bio Begins Phase I/II Trial of BBI-825 in Patients With Resistance Gene Amplifications
The company will evaluate BBI-825 as a monotherapy and in combination with EGFR, BRAF, and KRAS inhibitors.
BMS's Krazati, Erbitux Combo Shows Potential as Standard Therapy in KRAS-Mutant Colorectal Cancer
Premium
Patients with a historically poor prognosis had median overall survival of 15.9 months in a pooled Phase I/II analysis reported at AACR's annual meeting.
Data from retrospective RNA profiling of more than 900 patients challenges prior studies suggesting high HER2 expression as an EGFR inhibitor resistance marker.